These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33917026)
1. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response. Zhang L; Ramesh P; Steinmetz M; Medema JP Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026 [TBL] [Abstract][Full Text] [Related]
2. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
3. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825 [TBL] [Abstract][Full Text] [Related]
4. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related]
5. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218 [TBL] [Abstract][Full Text] [Related]
6. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy. Ramesh P; Medema JP Apoptosis; 2020 Jun; 25(5-6):305-320. PubMed ID: 32335811 [TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900 [TBL] [Abstract][Full Text] [Related]
8. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070 [TBL] [Abstract][Full Text] [Related]
9. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells. Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072 [TBL] [Abstract][Full Text] [Related]
10. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701 [TBL] [Abstract][Full Text] [Related]
12. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Ewald L; Dittmann J; Vogler M; Fulda S Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941 [TBL] [Abstract][Full Text] [Related]
13. CRISPR screens identify a novel combination treatment targeting BCL-X Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570 [TBL] [Abstract][Full Text] [Related]
14. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment. Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755 [TBL] [Abstract][Full Text] [Related]
15. By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737. Tailler M; Lindqvist LM; Gibson L; Adams JM Cell Death Differ; 2019 Sep; 26(9):1766-1781. PubMed ID: 30538285 [TBL] [Abstract][Full Text] [Related]
16. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides. Modi V; Sankararamakrishnan R J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
18. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830 [TBL] [Abstract][Full Text] [Related]
20. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]